Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18747461 | 0.96 | FFAR1 (0.34) | FFAR1FFAR4 | |
| SCHEMBL18746583 | 0.94 | FFAR1 (0.33) | FFAR1FFAR4 | |
| SCHEMBL18747707 | 0.94 | FFAR1 (0.37) | FFAR1FFAR4 | |
| SCHEMBL18747787 | 0.92 | FFAR1 (0.30) | FFAR1FFAR4 | |
| SCHEMBL18746718 | 0.92 | FFAR1 (0.34) | FFAR1FFAR4 | |
| SCHEMBL18747960 | 0.92 | FFAR1 (0.31) | FFAR1FFAR4 | |
| SCHEMBL18747860 | 0.91 | FFAR1 (0.36) | FFAR1FFAR4 | |
| SCHEMBL18747856 | 0.90 | FFAR1 (0.30) | FFAR1FFAR4 | |
| SCHEMBL18747074 | 0.90 | FFAR1 (0.30) | FFAR1FFAR4 | |
| SCHEMBL18746678 | 0.90 | FFAR1 (0.34) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156388-B1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLANE BACKBONE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-9879183-B2 | Liquid crystal compound having CF2O bonding group and tolan skeleton, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3156388-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLANE BACKBONE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, TLN1, TCOF1 | FFAR1 1553/4885FFAR4 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.